These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 35895223)
1. He L; Chen Y; Tan X; Sun X; Zhang Q; Luo H; Jiang L Jpn J Radiol; 2023 Jan; 41(1):98-107. PubMed ID: 35895223 [TBL] [Abstract][Full Text] [Related]
2. FDG-PET/ CT for initial staging and response assessment in Castleman disease - retrospective single-center study of 29 cases. Koukalová R; Selingerová I; Řehák Z; Adam Z; Szturz P Klin Onkol; 2021; 34(2):120-127. PubMed ID: 33906360 [TBL] [Abstract][Full Text] [Related]
3. 18F-FDG PET/CT imaging features of patients with multicentric Castleman disease. Jiang Y; Hou G; Zhu Z; Huo L; Li F; Cheng W Nucl Med Commun; 2021 Jul; 42(7):833-838. PubMed ID: 33741858 [TBL] [Abstract][Full Text] [Related]
4. The value of multiparameter Jiang Y; Hou G; Zhu Z; Huo L; Cheng W; Li F Sci Rep; 2020 Jul; 10(1):12887. PubMed ID: 32732920 [TBL] [Abstract][Full Text] [Related]
6. Correlation between Zhao J; Wang H J Med Imaging Radiat Oncol; 2021 Apr; 65(2):188-194. PubMed ID: 33538120 [TBL] [Abstract][Full Text] [Related]
7. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
8. Diagnostic Contribution of Contrast-Enhanced CT as Compared with Unenhanced Low-Dose CT in PET/CT Staging and Treatment Response Assessment of Marchetti L; Perrucci L; Pellegrino F; Baroni L; Merlo A; Tilli M; Rambaldi I; Maietti E; Carnevale A; Bartolomei M; Giganti M J Nucl Med; 2021 Oct; 62(10):1372-1379. PubMed ID: 33712534 [TBL] [Abstract][Full Text] [Related]
9. Added value of pretreatment (18)F-FDG PET/CT for staging of advanced gastric cancer: Comparison with contrast-enhanced MDCT. Kawanaka Y; Kitajima K; Fukushima K; Mouri M; Doi H; Oshima T; Niwa H; Kaibe N; Sasako M; Tomita T; Miwa H; Hirota S Eur J Radiol; 2016 May; 85(5):989-95. PubMed ID: 27130061 [TBL] [Abstract][Full Text] [Related]
10. Prognostic and diagnostic value of [18F]FDG-PET/CT in restaging patients with small cell lung carcinoma: an Italian multicenter study. Quartuccio N; Evangelista L; Alongi P; Caobelli F; Altini C; Cistaro A; Lambertini A; Schiorlin I; Popescu CE; Linguanti F; Laudicella R; Scalorbi F; Di Pierro G; Asabella AN; Cuppari L; Margotti S; Lima GM; Scalisi S; Pacella S; Kokomani A; Ciaccio A; Sturiale L; Vento A; Cardile D; Baldari S; Panareo S; Fanti S; Rubini G; Schillaci O; Chiaravalloti A; Nucl Med Commun; 2019 Aug; 40(8):808-814. PubMed ID: 31136534 [TBL] [Abstract][Full Text] [Related]
11. Diagnostic and prognostic value of 18F-FDG PET/CT in comparison with morphological imaging in primary adrenal gland malignancies - a multicenter experience. Cistaro A; Niccoli Asabella A; Coppolino P; Quartuccio N; Altini C; Cucinotta M; Alongi P; Balma M; Sanfilippo S; Buschiazzo A; Piccardo A; Fanelli M; Sambuceti G; Bomanji J; Baldari S; Bisi G; Fanti S; Rubini G Hell J Nucl Med; 2015; 18(2):97-102. PubMed ID: 26187207 [TBL] [Abstract][Full Text] [Related]
12. The value of (18) F-FDG-PET/CT imaging in oral cavity cancer patients following surgical reconstruction. Müller J; Hüllner M; Strobel K; Huber GF; Burger IA; Haerle SK Laryngoscope; 2015 Aug; 125(8):1861-8. PubMed ID: 25892275 [TBL] [Abstract][Full Text] [Related]
13. The correlation of Qu YH; Long N; Ran C; Sun J Clin Transl Oncol; 2021 Mar; 23(3):620-627. PubMed ID: 32683540 [TBL] [Abstract][Full Text] [Related]
14. [Role of 18F-FDG PET/CT in comparison with CECT for whole-body assessment of patients with esophageal cancer.]. Altini C; Niccoli Asabella A; Lavelli V; Bianco G; Ungaro A; Pisani A; Merenda N; Ferrari C; Rubini G Recenti Prog Med; 2019 Mar; 110(3):144-150. PubMed ID: 30968855 [TBL] [Abstract][Full Text] [Related]
15. Diagnostic challenges in primary cardiac lymphoma, the opportunity of Liu E; Huang J; Dong H; Chen Z; Liu C; Xie Q; Xu W; Wang S; Liu Z J Nucl Cardiol; 2022 Oct; 29(5):2378-2389. PubMed ID: 34318397 [TBL] [Abstract][Full Text] [Related]
16. Can full-dose contrast-enhanced CT be omitted from an FDG-PET/CT staging examination in newly diagnosed FDG-avid lymphoma? van Hamersvelt HP; Kwee TC; Fijnheer R; Beek FJ; de Klerk JM; Nievelstein RA J Comput Assist Tomogr; 2014; 38(4):620-5. PubMed ID: 24681861 [TBL] [Abstract][Full Text] [Related]
17. García Vicente AM; Talavera Rubio MP; Dominguez Ferreras E; Calle Primo C; Amo-Salas M; Tello Galán MJ; Jiménez Londoño GA; Jiménez Aragón F; Hernández Ruiz B; Soriano Castrejón Á Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(3):151-155. PubMed ID: 29107751 [TBL] [Abstract][Full Text] [Related]
18. Should 18F-FDG PET/CT Be Routinely Performed in the Clinical Staging of Locally Advanced Gastric Adenocarcinoma? Perlaza P; Ortín J; Pagès M; Buxó E; Fernández-Esparrach G; Colletti PM; Rubello D; Mayoral M; Sánchez N; Ruiz C; Ginés A; Fuster D Clin Nucl Med; 2018 Jun; 43(6):402-410. PubMed ID: 29485442 [TBL] [Abstract][Full Text] [Related]
19. The role of Rufini V; Collarino A; Calcagni ML; Meduri GM; Fuoco V; Pasciuto T; Testa AC; Ferrandina G; Gambacorta MA; Campitelli M; Gui B; Zannoni G; Manfredi R; Scambia G; Giordano A Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1228-1238. PubMed ID: 31414206 [TBL] [Abstract][Full Text] [Related]